Centocor gets exclusive rights to FivePrime compounds
Johnson & Johnson's Centocor Research & Development has signed a deal with FivePrime Therapeutics to discover and develop pulmonary fibrosis and osteoarthritis compounds (specifically focusing on cartilage repair and regeneration).
- Large Molecule
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com